Petmed Express Inc (PETS) Receives Average Recommendation of “Sell” from Analysts

Shares of Petmed Express Inc (NASDAQ:PETS) have been given a consensus recommendation of “Sell” by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $18.00.

PETS has been the topic of a number of recent analyst reports. BidaskClub cut shares of Petmed Express from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Craig Hallum reduced their price target on shares of Petmed Express from $25.00 to $18.00 and set a “sell” rating on the stock in a research report on Wednesday, January 23rd. Finally, ValuEngine cut shares of Petmed Express from a “hold” rating to a “sell” rating in a research report on Monday, February 4th.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Great West Life Assurance Co. Can lifted its position in Petmed Express by 2.0% in the 4th quarter. Great West Life Assurance Co. Can now owns 26,411 shares of the company’s stock valued at $566,000 after acquiring an additional 508 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Petmed Express by 688.3% during the third quarter. JPMorgan Chase & Co. now owns 58,130 shares of the company’s stock worth $1,919,000 after buying an additional 50,756 shares during the period. Canada Pension Plan Investment Board increased its position in shares of Petmed Express by 46.3% during the fourth quarter. Canada Pension Plan Investment Board now owns 135,200 shares of the company’s stock worth $3,144,000 after buying an additional 42,800 shares during the period. Morgan Stanley increased its position in shares of Petmed Express by 110.1% during the third quarter. Morgan Stanley now owns 312,416 shares of the company’s stock worth $10,313,000 after buying an additional 163,691 shares during the period. Finally, Oregon Public Employees Retirement Fund acquired a new stake in shares of Petmed Express during the fourth quarter worth $183,000. 95.04% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:PETS traded up $0.33 during mid-day trading on Tuesday, hitting $22.31. The company’s stock had a trading volume of 680,871 shares, compared to its average volume of 525,335. Petmed Express has a fifty-two week low of $20.25 and a fifty-two week high of $46.83. The firm has a market capitalization of $461.24 million, a PE ratio of 11.04 and a beta of 0.51.

Petmed Express (NASDAQ:PETS) last posted its quarterly earnings data on Tuesday, January 22nd. The company reported $0.38 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.48 by ($0.10). The firm had revenue of $60.10 million for the quarter, compared to analyst estimates of $64.22 million. Petmed Express had a return on equity of 32.89% and a net margin of 14.43%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business posted $0.44 EPS.

About Petmed Express

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Featured Story: Technical Analysis

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.